Halozyme Therapeutics, Inc. (HALO)
110.75
+1.09
(+0.99%)
USD |
NASDAQ |
Sep 03, 16:00
110.75
0.00 (0.00%)
After-Hours: 17:41
Halozyme Therapeutics Cash from Operations (Annual) : 651.56M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 651.56M |
| December 31, 2024 | 479.06M |
| December 31, 2023 | 388.57M |
| December 31, 2022 | 240.11M |
| December 31, 2021 | 299.44M |
| December 31, 2020 | 55.45M |
| December 31, 2019 | -85.42M |
| December 31, 2018 | -49.50M |
| December 31, 2017 | 134.05M |
| December 31, 2016 | -50.38M |
| December 31, 2015 | -37.08M |
| December 31, 2014 | -47.52M |
| December 31, 2013 | -49.24M |
| Date | Value |
|---|---|
| December 31, 2012 | -64.33M |
| December 31, 2011 | -34.35M |
| December 31, 2010 | -45.39M |
| December 31, 2009 | -40.15M |
| December 31, 2008 | -35.37M |
| December 31, 2007 | -0.1477M |
| December 31, 2006 | 7.080M |
| December 31, 2005 | -13.00M |
| December 31, 2004 | -7.718M |
| December 31, 2003 | -0.0497M |
| December 31, 2002 | -0.0558M |
| December 31, 2001 | -0.0344M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Incyte Corp. | 1.413B |
| AVITA Medical, Inc. | -31.20M |
| Neurocrine Biosciences, Inc. | 782.70M |
| Iovance Biotherapeutics, Inc. | -302.41M |
| Editas Medicine, Inc. | -165.24M |